GlassScriptPhysician profile
Smita N Kargutkar
NPI 1043482631
$32,750.57
in general payments reported to CMS, 2019-2025
62 companies · $1,716 in 2025
The $1,716 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $7,778 · 2020: $4,458 · 2021: $7,348 · 2022: $5,903 · 2023: $4,037 · 2024: $1,511 · 2025: $1,716.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,320 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,100 · Honoraria: $700 · Education: $143.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,319.80 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,100.00 |
| Honoraria | $700.00 |
| Education | $143.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $12,710.06 | 2019-2025 | |
| Corcept Therapeutics | $8,608.96 | 2019-2025 | Korlym |
| Novo Nordisk INC | $1,663.11 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Xeris Pharmaceuticals, INC. | $1,219.69 | 2021-2025 | Recorlev, Gvoke Hypopen |
| Amneal Pharmaceuticals LLC | $912.51 | 2019-2025 | Unithroid |
| Lilly USA, LLC | $897.09 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Senseonics, Incorporated | $866.00 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $672.64 | 2019-2023 | Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $535.30 | 2019-2025 | Jardiance |
| Sanofi-Aventis U.S. LLC | $404.76 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $325.59 | 2019-2023 | Steglatro, Steglujan, Januvia |
| Currax Pharmaceuticals LLC | $322.66 | 2020-2023 | Contrave, Nexletol |
| Dexcom, INC. | $320.62 | 2019-2025 | Dexcom G6 Transmitter |
| Amgen INC. | $320.42 | 2019-2025 | Tepezza, Evenity, Prolia |
| Amarin Pharma, INC. | $298.46 | 2019-2022 |
Show all 62 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $249.46 | 2019-2024 | Freestyle Libre 3 |
| Opko Pharmaceuticals, LLC | $246.28 | 2019-2025 | Rayaldee |
| Ibsa Pharma INC. | $190.19 | 2019-2025 | Flector, Licart, Tirosint |
| Alexion Pharmaceuticals, INC. | $164.74 | 2020-2025 | Strensiq |
| Insulet Corporation | $147.08 | 2019-2025 | Omnipod |
| Bayer Healthcare Pharmaceuticals INC. | $137.22 | 2021-2025 | |
| Recordati_rare_diseases_inc. | $127.55 | 2020-2025 | Isturisa, Signifor Lar |
| Janssen Pharmaceuticals, INC | $94.21 | 2019-2020 | |
| Medtronic Minimed, INC. | $81.12 | 2019-2020 | |
| Pfizer INC. | $79.28 | 2019-2022 | |
| Neurocrine Biosciences, INC. | $73.59 | 2024-2025 | |
| Amryt Pharma Holdings LTD | $70.84 | 2021-2023 | Myalept |
| Antares Pharma, INC. | $64.15 | 2021-2023 | Xyosted, Nocdurna, Tlando |
| Mannkind Corporation | $62.34 | 2019-2024 | |
| Acella Pharmaceuticals, LLC | $61.64 | 2022-2025 | NP Thyroid 60 |
| Medtronic, INC. | $56.33 | 2021-2023 | Minimed 780g |
| Rhythm Pharmaceuticals, INC. | $52.33 | 2022-2024 | Imcivree, Imcivree |
| Eisai INC. | $47.85 | 2019 | |
| Echosens North America, INC. | $45.68 | 2023 | Fibroscan |
| Tandem Diabetes Care, INC. | $41.60 | 2023-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Nalpropion Pharmaceuticals LLC | $41.06 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $39.76 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $38.65 | 2020-2021 | |
| Chiesi USA, INC. | $33.54 | 2024-2025 | Myalept |
| Beta Bionics, INC. | $33.54 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Zealand Pharma US, INC. | $31.64 | 2021 | |
| Intra-Sana Laboratories | $29.05 | 2023 | Glycate, Reltone 200 Mg, Reltone 400 Mg |
| Vistapharm, INC. | $26.90 | 2021 | |
| Shire North American Group INC | $25.79 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $25.21 | 2019 | |
| Cequr Corporation | $24.04 | 2022-2024 | Cequr Simplicity |
| Soleno Therapeutics, INC. | $19.59 | 2025 | Vykat Xr |
| Sequel Med Tech, LLC | $18.22 | 2025 | Twiist |
| Madrigal Pharmaceuticals | $17.68 | 2025 | Rezdiffra |
| Lifescan, INC. | $16.23 | 2022 | |
| Alnylam Pharmaceuticals INC. | $15.07 | 2024 | Amvuttra |
| Valeritas, INC. | $14.76 | 2019 | |
| Ascendis Pharma Endocrinology INC | $13.86 | 2023 | |
| Ascensia Diabetes Care US INC. | $13.69 | 2024 | |
| Halozyme INC | $13.51 | 2023 | |
| Vivus LLC | $13.33 | 2022 | |
| Lexicon Pharmaceuticals, INC. | $13.16 | 2023 | Inpefa |
| Astellas Pharma US INC | $13.06 | 2023 | Veozah |
| Embecta Corp. | $12.74 | 2023 | Bd Nano 2nd Gen Pen Needle |
| Eusa Pharma (US) LLC | $12.17 | 2022 | |
| Becton, Dickinson and Company | $11.68 | 2022 | |
| Chiasma, INC. | $11.29 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Smita Kargutkar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.